ReviewFrontiers in oncology2026
Translating advances in primary central nervous system lymphoma: from prognostic stratification to treatment innovation.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary central nervous system lymphoma (PCNSL) is a rare but aggressive diffuse large B-cell lymphoma confined to the CNS, characterized by unique clinical behavior and therapeutic challenges. Outcomes have improved with high-dose methotrexate (HD-MTX)-based regimens, but relapse, treatment toxicity, and age-related frailty remain major barriers. This review synthesizes advances in prognostic stratification and treatment of PCNSL. We highlight two validated clinical models (IELSG and MSKCC) and emerging genomic biomarkers that refine risk assessment. HD-MTX-based induction (MTR, R-MPV, MATRix, R-MBVP) is the standard first-line approach for fit patients, including many older adults. Consolidation with thiotepa-based high-dose chemotherapy and autologous stem-cell transplantation (HDC-ASCT) yields durable disease control in eligible patients, whereas non-myeloablative cytarabine-based chemotherapy or reduced-dose whole-brain radiotherapy remains an option for those unfit for transplant. In relapsed disease, methotrexate rechallenge benefits prior responders, while BTK- or IMiD-based regimens, CAR-T therapy, and focal or whole-brain radiotherapy are under active investigation. Maintenance with HD-MTX or targeted agents shows promise but requires validation. Although therapeutic outcomes have steadily improved, particularly with HD-MTX-based induction and HDC-ASCT consolidation, long-term survival for elderly and relapsed patients remains unsatisfactory. The integration of molecular biomarkers, neurotoxicity-sparing consolidation, and novel immunotherapies may further individualize treatment and improve the durability of remission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.